Suppression of peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer

International Journal of Medical Sciences

Volumn 11, Issue 9, 2014, Pages 870-879

  Zhang, Dongmei ^a   Zheng, Lan ^b   Shi, Huashan ^a   Chen, Xiancheng ^a   Wan, Yang ^a   Zhang, Hailong ^a   Li, Meng ^a   Lu, Lian ^a   Luo, Shuntao ^a   Yin, Tao ^a   Lin, Honggang ^a   He, Shasha ^a   Luo, Yan ^a   Yang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ADENOVIRUS VECTOR; BETA1 INTEGRIN; ENDOGLIN; ENDOSTATIN; LIPOFECTAMINE; THY 1 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMATOUS PERITONITIS; CELL DIFFERENTIATION; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; STEM CELL GENE THERAPY; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; CARCINOGENESIS; COLORECTAL TUMOR; CYTOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PERITONEUM; PLACENTA; PREGNANCY;

ADENOVIRIDAE; ANIMALS; CARCINOGENESIS; COLORECTAL NEOPLASMS; ENDOSTATINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; PERITONEUM; PLACENTA; PREGNANCY;

EID: 84903265972     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8758     Document Type: Article

References (46)

1. Nie B, Shen Z, Wen JB, Wong OG, Hsueh WD, Huo LF, et al. AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Molecular cancer therapeutics. 2008; 7: 2855-65. doi:10.1158/1535-7163.MCT-08-0366.
2. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. The British journal of surgery. 2002; 89: 1545-50. doi:10.1046/j.1365-2168.2002.02274.x.
3. Wang Y, Gong C, Yang L, Wu Q, Shi S, Shi H, et al. 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC cancer. 2010; 10: 402. doi:10.1186/1471-2407-10-402.
4. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia. 1999; 1: 293-302.
5. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature medicine. 2001; 7: 1194-201. doi:10.1038/nm1101-1194.
6. Folkman J, Watson K, Ingber D, Hanahan D. Induction of Angiogenesis during the Transition from Hyperplasia to Neoplasia. Nature. 1989; 339: 58-61.
7. Sakimoto I, Ohta K, Yamazaki T, Ohtani S, Sahara H, Sugawara F, et al. Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer research. 2006; 66: 2287-95. doi:10.1158/0008-5472.CAN-05-2209.
8. Tandle A, Blazer DG, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments. Journal of translational medicine. 2004; 2: 22. doi:10.1186/1479-5876-2-22.
9. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Molecular cell. 2004; 13: 649-63.
10. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer research. 2005; 65: 3656-63. doi:10.1158/0008-5472.CAN-04-1833.
11. Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PloS one. 2012; 7: e34646. doi:10.1371/journal.pone.0034646.
12. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, et al. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Molecular cancer therapeutics. 2005; 4: 956-67. doi:10.1158/1535-7163.MCT-04-0321.
13. Greco SJ, Rameshwar P. Enhancing effect of IL-1alpha on neurogenesis from adult human mesenchymal stem cells: implication for inflammatory mediators in regenerative medicine. J Immunol. 2007; 179: 3342-50.
14. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood. 2011; 118: 330-8. doi:10.1182/blood-2010-12-327353.
15. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Molecular cancer therapeutics. 2006; 5: 755-66. doi:10.1158/1535-7163.MCT-05-0334.
16. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene therapy. 2004; 11: 1155-64. doi:10.1038/sj.gt.3302276.
17. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol. 2006; 177: 2080-7.
18. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005; 2: 8. doi:10.1186/1476-9255-2-8.
19. Kemp KC, Hows J, Donaldson C. Bone marrow-derived mesenchymal stem cells. Leukemia & lymphoma. 2005; 46: 1531-44. doi:10.1080/10428190500215076.
20. Deak E, Seifried E, Henschler R. Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. International reviews of immunology. 2010; 29: 514-29. doi:10.3109/08830185.2010.498931.
21. Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, et al. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell biology international. 2006; 30: 681-7. doi:10.1016/j.cellbi.2006.03.009.
22. In't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004; 22: 1338-45. doi:10.1634/stemcells.2004-0058.
23. Zhang D, Tong A, Zhou L, Fang F, Guo G. Osteogenic differentiation of human placenta-derived mesenchymal stem cells (PMSCs) on electrospun nanofiber meshes. Cytotechnology. 2012. doi:10.1007/s10616-012-9450-5.
24. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science. 2005; 309: 1074-8. doi:10.1126/science.1110955.
25. Huang YC, Yang ZM, Chen XH, Tan MY, Wang J, Li XQ, et al. Isolation of mesenchymal stem cells from human placental decidua basalis and resistance to hypoxia and serum deprivation. Stem cell reviews. 2009; 5: 247-55. doi:10.1007/s12015-009-9069-x.
26. Murdoch AD, Grady LM, Ablett MP, Katopodi T, Meadows RS, Hardingham TE. Chondrogenic differentiation of human bone marrow stem cells in transwell cultures: generation of scaffold-free cartilage. Stem Cells. 2007; 25: 2786-96. doi:10.1634/stemcells.2007-0374.
27. Menon LG, Picinich S, Koneru R, Gao H, Lin SY, Koneru M, et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells. 2007; 25: 520-8. doi:10.1634/stemcells.2006-0257.
28. Tsai AC, Pan SL, Sun HL, Wang CY, Peng CY, Wang SW, et al. CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation. The Journal of biological chemistry. 2010; 285: 5497-506. doi:10.1074/jbc.M109.036277.
29. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell stem cell. 2009; 4: 206-16. doi:10.1016/j.stem.2009.02.001.
30. Brideau G, Makinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer research. 2007; 67: 11528-35. doi:10.1158/0008-5472.CAN-07-1458.
31. Noro T, Miyake K, Suzuki-Miyake N, Igarashi T, Uchida E, Misawa T, et al. Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer research. 2004; 64: 7486-90. doi:10.1158/0008-5472.CAN-03-1296.
32. Holst PJ, Orskov C, Thomsen AR, Christensen JP. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol. 2010; 184: 4431-9. doi:10.4049/jimmunol.0900537.
33. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Molecular therapy: the journal of the American Society of Gene Therapy. 2004; 10: 616-29. doi:10.1016/j.ymthe.2004.07.013.
34. Thaci B, Ulasov IV, Wainwright DA, Lesniak MS. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget. 2011; 2: 113-21.
35. Friedenstein AJ, Piatetzky S, Petrakova KV. Osteogenesis in transplants of bone marrow cells. Journal of embryology and experimental morphology. 1966; 16: 381-90.
36. Stappenbeck TS, Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science. 2009; 324: 1666-9. doi:10.1126/science.1172687.
37. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25: 2739-49. doi:10.1634/stemcells.2007-0197.
38. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer research. 2008; 68: 9614-23. doi:10.1158/0008-5472.CAN-08-0451.
39. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer research. 2002; 62: 3603-8.
40. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Experimental hematology. 2005; 33: 1402-16. doi:10.1016/j.exphem.2005.07.003.
41. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute. 2004; 96: 1593-603. doi:10.1093/jnci/djh299.
42. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011; 32: 477-87. doi:10.1093/carcin/bgr009.
43. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 557-63. doi:10.1038/nature06188.
44. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer biology & therapy. 2008; 7: 245-51.
45. Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, et al. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15: 7175-85. doi:10.1158/1078-0432.CCR-09-1938.
46. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62. doi:10.1126/science.1104819.